Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published (2)

STOCKHOLM, April 4, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that...

Related Keywords

Uppsala ,Uppsala Lan ,Sweden ,China ,Japan ,Stockholm ,Swedish ,Oskar Bosson ,Ministry Of Health ,Advisory Committee ,National Medical Products Administration ,Devices Agency ,Nasdaq ,Washington University School Of Medicine ,European Medicines Agency ,National Institutes Of Health ,National Institute On ,Uppsala University ,Drug Administration ,Translational Research Clinical Interventions ,Vp Communications ,Alzheimer Clinical Trial Consortium ,Alzheimer Network Trials Unit ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Medical Devices Agency ,Brand Name ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Commercialization Agreement ,Nasdaq Stockholm Large Cap ,Translational Research ,